Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1300 of 2873 entries
View as:

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00493571 Org: User:
Start: 08/31/07 End: 05/31/14 Due: 05/31/15

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00563784 Org: User:
Start: 11/30/07 End: 05/30/18 Due: 05/30/19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05761951 Org: User:
Start: 08/29/23 End: 01/31/29 Due: 01/31/30

Amifostine in Treating Patients With Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00003048 Org: User:
Start: 06/05/97 End: 02/12/01 Due: 02/12/02

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Phase: N/A Priority: Normal
NCT ID: NCT04983901 Org: User:
Start: 09/14/21 End: 10/06/23 Due: 10/06/24

Thymoglobulin (ATG) Dose Finding Study

Phase: N/A Priority: Normal
NCT ID: NCT00409695 Org: User:
Start: 12/31/06 End: 08/31/07 Due: 08/31/08

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Phase: N/A Priority: Normal
NCT ID: NCT00255346 Org: User:
Start: 11/15/05 End: 03/03/17 Due: 03/03/18

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Phase: N/A Priority: Normal
NCT ID: NCT00903734 Org: User:
Start: 04/30/09 End: - Due: -

Iressa Study in Patients With Salivary Gland Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00509002 Org: User:
Start: 05/31/04 End: 09/30/16 Due: 09/30/17

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00429026 Org: User:
Start: 01/31/04 End: 03/31/08 Due: 03/31/09

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT05675579 Org: User:
Start: 05/23/23 End: 12/31/26 Due: 12/31/27

Expressive Writing for the Management of Stress in Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT04776941 Org: User:
Start: 08/07/20 End: 12/31/28 Due: 12/31/29

Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Phase: N/A Priority: Normal
NCT ID: NCT05029752 Org: User:
Start: 06/30/21 End: 06/30/26 Due: 06/30/27

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)

Phase: N/A Priority: Normal
NCT ID: NCT05466994 Org: User:
Start: 08/19/22 End: 10/31/26 Due: 10/31/27

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Phase: N/A Priority: Normal
NCT ID: NCT02159872 Org: User:
Start: 05/18/15 End: 04/14/20 Due: 04/14/21

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05683171 Org: User:
Start: 05/19/23 End: 09/30/25 Due: 09/30/26

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06567314 Org: User:
Start: 12/02/24 End: 09/01/30 Due: 09/01/31

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Phase: N/A Priority: Normal
NCT ID: NCT06066424 Org: User:
Start: 10/24/23 End: 04/30/40 Due: 04/30/41

Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems

Phase: N/A Priority: Normal
NCT ID: NCT06843720 Org: User:
Start: 08/31/25 End: 03/31/31 Due: 03/31/32

The Effect of the Prostate Cancer Foundation Screening Guidelines for Black Men on Intention to Screen in Faith-based Communities

Phase: N/A Priority: Normal
NCT ID: NCT06838325 Org: User:
Start: 02/06/25 End: 01/31/28 Due: 01/31/29

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04616183 Org: User:
Start: 12/02/20 End: 12/31/25 Due: 12/31/26

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04785287 Org: User:
Start: 03/29/21 End: 05/27/27 Due: 05/27/28

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02427620 Org: User:
Start: 06/03/15 End: 06/30/27 Due: 06/30/28

A Digital Art Activity to Enhance Self-Disclosure and the Detection of Psycho-social Distress in Adult Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06127121 Org: User:
Start: 11/02/23 End: 08/31/25 Due: 08/31/26

A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05155423 Org: User:
Start: 04/21/18 End: 05/24/26 Due: 05/24/27